Andy Watts - Basic principles of drug design 3 - Neuraminidase Inhibitors Flashcards

1
Q

What type of drug design was used in the discovery of Neuraminidase inhibitors?

A
  • Structure based rational drug design
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the function of neuraminidase?

A
  • Releases new virons from infected cells by hydrolysing interactions between HA on the virus and sialyic acid conjugates on host cell membrane so they can reinfect
  • Degrades protective mucus layer covering epithelial host cells allowing the virus to reach the surface of epithelial cells
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is the function of haemagglutamin?

A
  • Attaches flu virus to cell surface
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Why does resistance occur in the flu virus?

A
  • Flu virus varies amino acids present in NA and HA antigens
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

In the chronology of Neuraminidase inhibitor design, what first took place?
- What happened?

A
  • Random screening for NA inhibitors?

- No success in screening compounds with potential for NA inhibition

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What happened after random screening of compounds took place?

A
  • Decided use mechanism based design
  • Started designing a mechanism based transition state inhibitor
  • Managed to isolate the enzyme and study it’s crystal structure by X-ray crystallography and molecular modelling
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What did isolation and investigations into the NA enzyme reveal?

A
  • That the enzymes active site is made up of 18 AAs which remain constant between each version of NA
  • Active site different to comparable mammalian enzymes so any inhibitor designed may be selective antivirals
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

When the enzyme was crystallised with sialic acid bound to its active site and the structure determined by X-ray crystallography, what happened next?

A
  • A molecular model of the complex was created resembling the crystal structure
  • Showed that carboxylate ion of sialic acid was bound to active site through H bonds and ionic interactions
  • Also interactions with hydrophobic pocket
  • Developed a proposed hydrolysis mechanism of action for release of virion
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What did the transition state intermediate possess that sialic acid analogues would’ve benefitted from?
Why would they benefit from this?
What was a disadvantage of this?
How was this disadvantage overcome?

A
  • A double bond between positions C2 and C3
  • Caused the same trigonal geometry at C2 as seen in the transition intermediate
  • OH bond at C2 was lost resulting in lower H bonds with active site
  • The loss of H bond interactions was made up by the fact that the inhibitor did not need to distort from chair shape in order to bind - saving energy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What was done after the addition of a double bond to sialic acid analogues between carbon 2 and 3?

A
  • Molecular modelling software was used to see most favourable conformation for H bond interactions
  • Found that binding region that the OH group in the 4 position usually interacts with can also interact with NH2 or guanidinium ions at C4
  • Molecules with these groups were modelled in the active site to see if there was room for the groups
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What were the results of modelling the sialic acid analogues with NH2 group in place of the OH at position 4?

A
  • Adding the NH2 group made the molecule more potent
  • More selective for viral enzyme over mammalian and bacterial
  • MORE BASIC GROUP HAS BETTER BINDING
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What were the results of modelling the sialic acid analogues with larger guanidinium group in place of the OH at position 4?
What drug is this?

A
  • Adding a larger NH-=NH2-NH2 group (guanidinium)
    found that this increased H bonding even more AND VAN DER WAALS
  • 100 fold increase in activity
  • MORE POTENT
  • Large group expelled water molecule from binding pocket creating a favourable entropic effect!

ZANAMIVIR!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is an issue with Zanamivir?

A
  • Polar nature means poor oral bioavailability
  • Has to be administered by inhalation
  • The drug is excreted unchanged by the kidney which is bad for resistance as there will be more Zanamivir in the environment
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

How was Tamiflu synthesised?

Step 1

A
  • Based on the structure of Zanamivir
  • Dihydropyan oxygen has no important role to play in binding to active site of NA
  • Decided to remove it
  • This way, the removal of polar oxygen means increased hydrophobicity = increased BA!
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

How was Tamiflu synthesised?
Step 2
What does this suggest?

A
  • Analoge created with double bond moved to replicate transition state of reaction
  • Transition state mimic so expected to bind more strongly and be more potent!
  • That the conformation of the ring is crucial for inhibitor activity as the substituents are the same after O removal but just analogue where double bond moved to replicate transition state
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

How was Tamiflu synthesised?

Step 3

A
  • Guanidine group was removed and replaced by NH2 to make it more soluble
  • Lost potency and specificity but gained BA
17
Q

How was Tamiflu synthesised?

Step 4

A
  • Glycerol side chain was removed to reduce polarity
  • Alkoxy analogues were synthesised to maximise hydrophobic interaction in the region of the active site that the glycerol side chain previously occupied
  • Found that the branched side chain CH(Et)2 was the most potent (alkoxy side chain)
  • Interacted with a large hydrophobic binding pocket only found in the viral enzyme making it more specific
18
Q

What was the final step in Tamiflu synthesis?

A
  • Made COOH group into an ethyl ester
  • Made a PRO DRUG to increase BA
  • Taken orally and then converted back to COOH
19
Q

How is Tamiflu metabolised?

A
  • De-esterification in the gut, liver and blood to active carboxylate
  • Active carboxylate has 80% BA
  • Excreted unchanged by the kidney (like Zanamivir)
20
Q

What are the issues with Tamiflu and resistance?

A
  • Influenza viruses have been seen to have resistance to Tamiflu
  • The mutations to the active site of the neuraminidase enzyme can be detected by the virus
  • Virus knows the difference between the usual substrate and the drug